​

Benitec Biopharma (BNTC) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

BNTC Stock Forecast

Benitec Biopharma (BNTC) stock forecast, based on 7 Wall Street analysts, predicts a 12-month average price target of $25.00, with a high of $25.00 and a low of $25.00. This represents a 123.61% increase from the last price of $11.18.

- $5 $10 $15 $20 $25 High: $25 Avg: $25 Low: $25 Last Closed Price: $11.18

BNTC Stock Rating

Benitec Biopharma stock's rating consensus is Buy, based on 7 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 6 Buy (85.71%), 1 Hold (14.29%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 7 0 1 6 Strong Sell Sell Hold Buy Strong Buy

BNTC Price Target Upside V Benchmarks

TypeNameUpside
StockBenitec Biopharma123.61%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-15
Avg Price Target-$25.00$28.60
Last Closing Price$11.18$11.18$11.18
Upside/Downside-123.61%155.81%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 2616---7
May, 2616---7
Apr, 2616---7
Mar, 2616---7
Feb, 2616---7
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 12, 2026Evercore ISI$25.00$12.01108.16%123.61%
Nov 24, 2025Raghuram SelvarajuH.C. Wainwright$32.00$13.26141.33%186.23%
Nov 04, 2025H.C. Wainwright$35.00$15.69123.07%213.06%
Nov 04, 2025JMP Securities$22.00$15.8638.71%96.78%
Sep 16, 2025Andreas ArgyridesOppenheimer$29.00$13.66112.30%159.39%
Oct 14, 2024Silvan TuerkcanJMP Securities$18.00$10.8665.75%61.00%
Oct 14, 2024Silvan TuerkcanJMP Securities$16.00$10.8647.33%43.11%
Oct 14, 2024Mani ForooharLeerink Partners$13.00$10.8619.71%16.28%
Sep 24, 2024Yasmeen RahimiPiper Sandler$30.00$8.88237.84%168.34%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jun 10, 2026UBSNeutraldowngrade
Jun 10, 2026GuggenheimBuyNeutraldowngrade
May 12, 2026Evercore ISIOutperforminitialise
Mar 09, 2026Cowen & Co.BuyBuyhold
Jan 12, 2026Cowen & Co.BuyBuyhold
Nov 04, 2025H.C. WainwrightBuyBuyhold
Nov 04, 2025CitigroupOutperformOutperformhold
Nov 04, 2025CitigroupMarket OutperformMarket Outperformhold
Sep 16, 2025OppenheimerOutperformOutperformhold
Nov 15, 2024Piper SandlerOverweightOverweighthold

Financial Forecast

EPS Forecast

$-80 $-62 $-44 $-26 $-8 $10 Jun 21 Jun 22 Jun 24 Jun 25 Jun 26 Jun 27 Jun 28 Jun 29
Jun 21Jun 22Jun 24Jun 25Jun 26Jun 27Jun 28Jun 29
Reported$-27.27$-19.31$-2.68$-1.05----
Avg Forecast$-77.94$-46.70$-7.17$-4.57$-6.67$-7.54$-5.83$5.86
High Forecast$-77.94$-46.70$-5.96$-1.68$-1.63$-2.41$-5.83$5.86
Low Forecast$-77.94$-46.70$-8.38$-11.75$-15.07$-19.97$-5.83$5.86
Surprise %-65.01%-58.65%-62.62%-77.02%----

Revenue Forecast

$0 $30M $60M $90M $120M $150M Jun 21 Jun 22 Jun 24 Jun 25 Jun 26 Jun 27 Jun 28 Jun 29
Jun 21Jun 22Jun 24Jun 25Jun 26Jun 27Jun 28Jun 29
Reported$59.00K$73.00K$216.00K-----
Avg Forecast$146.61K$145.35K$149.71K$1.12M$320.56K$95.81M$45.01M$145.19M
High Forecast$146.61K$145.35K$149.71K$1.12M$320.56K$95.81M$45.01M$145.19M
Low Forecast$146.61K$145.35K$149.71K$1.12M$320.56K$95.81M$45.01M$145.19M
Surprise %-59.76%-49.78%44.28%-----

Net Income Forecast

$-350M $-270M $-190M $-110M $-30M $50M Jun 21 Jun 22 Jun 24 Jun 25 Jun 26 Jun 27 Jun 28 Jun 29
Jun 21Jun 22Jun 24Jun 25Jun 26Jun 27Jun 28Jun 29
Reported$-13.88M$-18.21M$-21.75M$-37.92M----
Avg Forecast$-316.47M$-189.62M$-29.12M$-31.81M$-42.73M$-61.20M$-23.66M$23.79M
High Forecast$-316.47M$-189.62M$-24.19M$-6.84M$-6.63M$-9.79M$-23.66M$23.79M
Low Forecast$-316.47M$-189.62M$-34.04M$-47.70M$-61.19M$-81.09M$-23.66M$23.79M
Surprise %-95.61%-90.40%-25.30%19.18%----

BNTC Forecast FAQ

Is Benitec Biopharma stock a buy?

Benitec Biopharma stock has a consensus rating of Buy, based on 7 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 6 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Benitec Biopharma is a favorable investment for most analysts.

What is Benitec Biopharma's price target?

Benitec Biopharma's price target, set by 7 Wall Street analysts, averages $25 over the next 12 months. The price target range spans from $25 at the low end to $25 at the high end, suggesting a potential 123.61% change from the previous closing price of $11.18.

How does Benitec Biopharma stock forecast compare to its benchmarks?

Benitec Biopharma's stock forecast shows a 123.61% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Benitec Biopharma over the past three months?

  • June 2026: 14.29% Strong Buy, 85.71% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 14.29% Strong Buy, 85.71% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • April 2026: 14.29% Strong Buy, 85.71% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Benitec Biopharma’s EPS forecast?

Benitec Biopharma's average annual EPS forecast for its fiscal year ending in June 2026 is $-6.67, marking a 535.24% increase from the reported $-1.05 in 2025. Estimates for the following years are $-7.54 in 2027, $-5.83 in 2028, and $5.86 in 2029.

What is Benitec Biopharma’s revenue forecast?

Benitec Biopharma's average annual revenue forecast for its fiscal year ending in June 2026 is $320.56K, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $95.81M, followed by $45.01M for 2028, and $145.19M for 2029.

What is Benitec Biopharma’s net income forecast?

Benitec Biopharma's net income forecast for the fiscal year ending in June 2026 stands at $-42.732M, representing an 12.70% increase from the reported $-37.917M in 2025. Projections indicate $-61.204M in 2027, $-23.66M in 2028, and $23.79M in 2029.